CAR-T-CD19 with TriTE construct

CAR-T-CD19 with TriTE construct refers to a chimeric antigen receptor T cell (CAR T) therapy engineered to target the CD19 antigen, which is highly expressed on B-cell malignancies such as B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. The "TriTE" component suggests the inclusion of a trispecific T cell engager within the CAR T design, potentially enhancing tumor targeting or immune activation beyond standard CD19-directed CARs. Standard CD19-targeted CAR T cells are autologous or allogeneic T cells genetically modified to express a synthetic receptor that recognizes CD19 on malignant B cells, leading to their targeted destruction through cytotoxic mechanisms including cytokine release and direct lysis[1][2][3]. The addition of a TriTE (trispecific engager) may allow simultaneous engagement of multiple antigens or immune pathways, but specific details about this particular construct are not widely published in current literature. These therapies are typically developed for relapsed/refractory B-cell hematologic malignancies.